Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR3680 combined with docetaxel in prostate cancer
CTR20202072Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide, docetaxel in prostate cancer (PCa), prostate adenocarcinoma, sponsored by Hengrui Therapeutics. Started Dec 2020; status: active.
02
Drugs
rezvilutamidedocetaxel
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20202072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202072.